These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2505604)

  • 21. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
    Verstraete M; Arnold AE; Brower RW; Collen D; de Bono DP; De Zwaan C; Erbel R; Hillis WS; Lennane RJ; Lubsen J
    Am J Cardiol; 1987 Aug; 60(4):231-7. PubMed ID: 3113222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the initial bolus volume of recombinant tissue-type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Kumamoto University Myocardial Infarction Study (KUMIS) Group.
    Ogawa H; Yasue H; Oshima S; Ogata Y; Numata Y; Fujimoto K; Imoto N; Saito T; Hokamura Y; Takahashi T
    Jpn Circ J; 1995 Oct; 59(10):663-72. PubMed ID: 8558750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
    Arnold AE; Brower RW; Collen D; van Es GA; Lubsen J; Serruys PW; Simoons ML; Verstraete M
    J Am Coll Cardiol; 1989 Sep; 14(3):581-8. PubMed ID: 2504798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
    de Bono DP
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
    Mueller HS; Rao AK; Forman SA
    J Am Coll Cardiol; 1987 Sep; 10(3):479-90. PubMed ID: 3114349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
    Kawai C; Yui Y; Hosoda S; Nobuyoshi M; Suzuki S; Sato H; Takatsu F; Motomiya T; Kanmatsuse K; Kodama K; Yabe Y; Minamino T; Kimata S; Nakashima M
    J Am Coll Cardiol; 1997 Jun; 29(7):1447-53. PubMed ID: 9180103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction.
    Gemmill JD; Hogg KJ; MacIntyre PD; Booth N; Rae AP; Dunn FG; Hillis WS
    Br Heart J; 1991 Aug; 66(2):134-8. PubMed ID: 1909151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New substances and dosages for thrombolysis in acute myocardial infarct].
    Zeymer U; Neuhaus KL
    Z Kardiol; 1993; 82 Suppl 2():137-41. PubMed ID: 8328192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
    Koster RW; van Stralen R; McNeill AJ; Adgey AA; Fox KA; Dymond D; Sponzilli C; Jewitt D; Bucknall C; Kluft C
    Eur Heart J; 1990 Aug; 11(8):730-9. PubMed ID: 2118853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.
    Michels HR; Hoffman JJ; Bär FW
    J Thromb Thrombolysis; 1999 Oct; 8(3):213-21. PubMed ID: 10500311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators.
    Carney RJ; Murphy GA; Brandt TR; Daley PJ; Pickering E; White HJ; McDonough TJ; Vermilya SK; Teichman SL
    J Am Coll Cardiol; 1992 Jul; 20(1):17-23. PubMed ID: 1607520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
    Garabedian HD; Gold HK; Leinbach RC; Yasuda T; Johns JA; Collen D
    Am J Cardiol; 1986 Oct; 58(9):673-9. PubMed ID: 3094354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
    Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
    Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
    Williams DO; Borer J; Braunwald E; Chesebro JH; Cohen LS; Dalen J; Dodge HT; Francis CK; Knatterud G; Ludbrook P
    Circulation; 1986 Feb; 73(2):338-46. PubMed ID: 3080261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
    Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
    Jpn Circ J; 1991 Mar; 55(3):250-61. PubMed ID: 1903167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.